Literature DB >> 27281364

Influenza Activity - United States, 2015-16 Season and Composition of the 2016-17 Influenza Vaccine.

Stacy L Davlin, Lenee Blanton, Krista Kniss, Desiree Mustaquim, Sophie Smith, Natalie Kramer, Jessica Cohen, Charisse Nitura Cummings, Shikha Garg, Brendan Flannery, Alicia M Fry, Lisa A Grohskopf, Joseph Bresee, Teresa Wallis, Wendy Sessions, Rebecca Garten, Xiyan Xu, Anwar Isa Abd Elal, Larisa Gubareva, John Barnes, David E Wentworth, Erin Burns, Jacqueline Katz, Daniel Jernigan, Lynnette Brammer.   

Abstract

During the 2015-16 influenza season (October 4, 2015-May 21, 2016) in the United States, influenza activity* was lower and peaked later compared with the previous three seasons (2012-13, 2013-14, and 2014-15). Activity remained low from October 2015 until late December 2015 and peaked in mid-March 2016. During the most recent 18 influenza seasons (including this season), only two other seasons have peaked in March (2011-12 and 2005-06). Overall influenza activity was moderate this season, with a lower percentage of outpatient visits for influenza-like illness (ILI),(†) lower hospitalization rates, and a lower percentage of deaths attributed to pneumonia and influenza (P&I) compared with the preceding three seasons. Influenza A(H1N1)pdm09 viruses predominated overall, but influenza A(H3N2) viruses were more commonly identified from October to early December, and influenza B viruses were more commonly identified from mid-April through mid-May. The majority of viruses characterized this season were antigenically similar to the reference viruses representing the recommended components of the 2015-16 Northern Hemisphere influenza vaccine (1). This report summarizes influenza activity in the United States during the 2015-16 influenza season (October 4, 2015-May 21, 2016)(§) and reports the vaccine virus components recommended for the 2016-17 Northern Hemisphere influenza vaccines.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27281364     DOI: 10.15585/mmwr.mm6522a3

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  44 in total

1.  Prevention of Influenza Hospitalization Among Adults in the United States, 2015-2016: Results From the US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN).

Authors:  Jill M Ferdinands; Manjusha Gaglani; Emily T Martin; Don Middleton; Arnold S Monto; Kempapura Murthy; Fernanda P Silveira; H Keipp Talbot; Richard Zimmerman; Elif Alyanak; Courtney Strickland; Sarah Spencer; Alicia M Fry
Journal:  J Infect Dis       Date:  2019-09-13       Impact factor: 5.226

2.  Evaluation of correlates of protection against influenza A(H3N2) and A(H1N1)pdm09 infection: Applications to the hospitalized patient population.

Authors:  Joshua G Petrie; Emily T Martin; Rachel Truscon; Emileigh Johnson; Caroline K Cheng; E J McSpadden; Ryan E Malosh; Adam S Lauring; Lois E Lamerato; Maryna C Eichelberger; Jill M Ferdinands; Arnold S Monto
Journal:  Vaccine       Date:  2019-02-07       Impact factor: 3.641

3.  Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol.

Authors:  Rameshwar U Kadam; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-21       Impact factor: 11.205

4.  Comparative safety of high-dose versus standard-dose influenza vaccination in patients with end-stage renal disease.

Authors:  J Bradley Layton; Leah J McGrath; John M Sahrmann; Yinjiao Ma; Vikas R Dharnidharka; Caroline O'Neil; David J Weber; Anne M Butler
Journal:  Vaccine       Date:  2020-06-19       Impact factor: 3.641

5.  A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy Volunteer Human Challenge Model.

Authors:  Alison Han; Lindsay M Czajkowski; Amanda Donaldson; Holly Ann Baus; Susan M Reed; Rani S Athota; Tyler Bristol; Luz Angela Rosas; Adriana Cervantes-Medina; Jeffery K Taubenberger; Matthew J Memoli
Journal:  Clin Infect Dis       Date:  2019-11-27       Impact factor: 9.079

6.  Influenza A M2 recruits M1 to the plasma membrane: A fluorescence fluctuation microscopy study.

Authors:  Annett Petrich; Valentin Dunsing; Sara Bobone; Salvatore Chiantia
Journal:  Biophys J       Date:  2021-11-19       Impact factor: 4.033

7.  Evolution-informed forecasting of seasonal influenza A (H3N2).

Authors:  Xiangjun Du; Aaron A King; Robert J Woods; Mercedes Pascual
Journal:  Sci Transl Med       Date:  2017-10-25       Impact factor: 17.956

8.  Analysis of Health-Care Charges in Murine Typhus: Need for Improved Clinical Recognition and Diagnostics for Acute Disease.

Authors:  Rahat F Vohra; David H Walker; Lucas S Blanton
Journal:  Am J Trop Med Hyg       Date:  2018-04-05       Impact factor: 2.345

9.  Differential Effects of Prior Influenza Exposures on H3N2 Cross-reactivity of Human Postvaccination Sera.

Authors:  Hang Xie; Lei Li; Zhiping Ye; Xing Li; Ewan P Plant; Olga Zoueva; Yangqing Zhao; Xianghong Jing; Zhengshi Lin; Toshiaki Kawano; Meng-Jung Chiang; Courtney L Finch; Martina Kosikova; Anding Zhang; Yanhong Zhu; Xiu-Feng Wan
Journal:  Clin Infect Dis       Date:  2017-07-15       Impact factor: 9.079

10.  Impact of Immune Priming, Vaccination, and Infection on Influenza A(H3N2) Antibody Landscapes in Children.

Authors:  Michael Hinojosa; Samuel S Shepard; Jessie R Chung; Jennifer P King; Huong Q McLean; Brendan Flannery; Edward A Belongia; Min Z Levine
Journal:  J Infect Dis       Date:  2021-08-02       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.